Inclusion Criteria:  Current or previous treatment with benralizumab for SEA Physician-confirmed diagnosis and evaluation of NP using NPS and/or SNOT-22 before and after first benralizumab injection Patients who have follow-up period of at least 5 months from first benralizumab injection or at least 4 consecutive injections of benralizumab Able to provide signed informed consent (if required based on local guidelines)  Exclusion Criteria:  Patient on any other biologic during the 12 months prior to treatment with benralizumab Previously or currently receiving benralizumab or any other biologic for the treatment of asthma or NP in a clinical trial